Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
18
02
2021
pubmed:
21
2
2021
medline:
21
9
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Case-control studies report a dose-dependent increased risk of skin cancer in users of hydrochlorothiazide (HCTZ) vs. nonusers. The degree to which other thiazides and thiazide-like diuretics (TZs) are associated with skin cancer is less certain. To assess the risk of skin cancer in new users of different TZs compared with new users of calcium channel blockers (CCBs). We conducted a cohort study using a UK primary-care database (1998-2017), including 271 154 new TZ users [87·6% bendroflumethiazide (BFT), 5·8% indapamide and 3·6% HCTZ] and 275 263 CCB users. The outcomes were basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and cutaneous malignant melanoma (CMM). We estimated incidence rates (IRs) and IR ratios (IRRs) in short-term (< 20 prescriptions) and long-term (≥ 20 prescriptions) users of TZs and CCBs using negative binomial regression, and calculated rate differences (RDs) for selected results. We used fine stratification on the propensity score (PS) to control for 23 baseline covariates. Long-term use of HCTZ increased absolute and relative risks of SCC [PS-weighted IRR 1·95; 95% confidence interval (CI) 1·87-2·02; RD per 100 000 person-years 87.4], but not of BCC or CMM. Long-term use of indapamide was associated with an increased incidence of CMM (IRR 1·43; 95% CI 1·35-1·50). BFT was not meaningfully associated with the risk of any type of skin cancer. Our results corroborate the previously reported increased risk of SCC (but not of BCC or CMM) for long-term use of HCTZ. BFT may be a safer alternative for patients at increased risk of skin cancer.
Sections du résumé
BACKGROUND
Case-control studies report a dose-dependent increased risk of skin cancer in users of hydrochlorothiazide (HCTZ) vs. nonusers. The degree to which other thiazides and thiazide-like diuretics (TZs) are associated with skin cancer is less certain.
OBJECTIVES
To assess the risk of skin cancer in new users of different TZs compared with new users of calcium channel blockers (CCBs).
METHODS
We conducted a cohort study using a UK primary-care database (1998-2017), including 271 154 new TZ users [87·6% bendroflumethiazide (BFT), 5·8% indapamide and 3·6% HCTZ] and 275 263 CCB users. The outcomes were basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and cutaneous malignant melanoma (CMM). We estimated incidence rates (IRs) and IR ratios (IRRs) in short-term (< 20 prescriptions) and long-term (≥ 20 prescriptions) users of TZs and CCBs using negative binomial regression, and calculated rate differences (RDs) for selected results. We used fine stratification on the propensity score (PS) to control for 23 baseline covariates.
RESULTS
Long-term use of HCTZ increased absolute and relative risks of SCC [PS-weighted IRR 1·95; 95% confidence interval (CI) 1·87-2·02; RD per 100 000 person-years 87.4], but not of BCC or CMM. Long-term use of indapamide was associated with an increased incidence of CMM (IRR 1·43; 95% CI 1·35-1·50). BFT was not meaningfully associated with the risk of any type of skin cancer.
CONCLUSIONS
Our results corroborate the previously reported increased risk of SCC (but not of BCC or CMM) for long-term use of HCTZ. BFT may be a safer alternative for patients at increased risk of skin cancer.
Substances chimiques
Diuretics
0
Thiazides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-352Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2021 British Association of Dermatologists.
Références
Moser M, Feig PU. Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med 2009; 169:1851-6.
Williams B, Mancia G, Spiering W et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press 2018; 27:314-40.
Whelton PK, Carey RM. The 2017 clinical practice guideline for high blood pressure. JAMA 2017; 318:2073-4.
Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25:345-72.
Kreutz R, Algharably EAH, Douros A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J Hypertens 2019; 37:1950-8.
Some Drugs and Herbal Products. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 108. Lyon, France: International Agency for Research on Cancer, 2016. Available at: https://www.ncbi.nlm.nih.gov/books/NBK350406/ (last accessed 12 March 2021).
Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78:673-81.
Pottegård A, Pedersen SA, Schmidt SAJ et al. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med 2018; 178:1120-2.
European Medicines Agency. PRAC recommendations on signals. Available at: https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf (last accessed 12 March 2021).
Food and Drug Administration. FDA Advisory No. 2019-328. Safety Information: Risk of Non-melanoma skin cancer with prolonged use of hydrochlorothiazide. Available at: https://www.fda.gov.ph/fda-advisory-no-2019-328-safety-information-risk-of-non-melanoma-skin-cancer-with-prolonged-use-of-hydrochlorothiazide/ (last accessed 12 March 2021).
Pottegård A, Hallas J, Olesen M et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282:322-31.
Kaae J, Boyd HA, Hansen AV et al. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:2942-9.
Jensen AO, Thomsen HF, Engebjerg MC et al. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008; 99:1522-8.
Herrett E, Gallagher AM, Bhaskaran K et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44:827-36.
Herrett E, Thomas SL, Schoonen WM et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69:4-14.
Mathur R, Bhaskaran K, Chaturvedi N et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health (Oxf) 2014; 36:684-92.
Saunders CL, Abel GA, El Turabi A et al. Accuracy of routinely recorded ethnic group information compared with self-reported ethnicity: evidence from the English Cancer Patient Experience survey. BMJ Open 2013; 3:e002882.
Jack RH, Linklater KM, Hofman D et al. Ethnicity coding in a regional cancer registry and in Hospital Episode Statistics. BMC Public Health 2006; 6:281.
Meal A, Leonardi-Bee J, Smith C et al. Validation of THIN data for non-melanoma skin cancer. Qual Prim Care 2008; 16:49-52.
Margulis AV, Fortuny J, Kaye JA et al. Validation of cancer cases using primary care, cancer registry, and hospitalization data in the United Kingdom. Epidemiology 2018; 29:308-13.
Reinau D, Surber C, Jick SS, Meier CR. Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer. Int J Cancer 2015; 137:144-53.
Bellaney GJ, Proby CM, Hawk JL. Likely photosensitizing agents available in the United Kingdom - an update. Clin Exp Dermatol 1996; 21:14-6.
Robinson SN, Zens MS, Perry AE et al. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol 2013; 133:1950-5.
Friis S, Kesminiene A, Espina C et al. European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. Cancer Epidemiol 2015; 39 (Suppl. 1):S107-S119.
Desai RJ, Rothman KJ, Bateman BT et al. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology 2017; 28:249-57.
Morales D, Pacurariu A, Slattery J, Kurz X. Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: a series of population-based nested case-control studies. Br J Clin Pharmacol 2020; 86:1336-45.
Van Mulder TJ, de Koeijer M, Theeten H et al. High frequency ultrasound to assess skin thickness in healthy adults. Vaccine 2017; 35:1810-5.
Hansen MR, Bentzen J. High-risk sun-tanning behaviour: a quantitative study in Denmark, 2008-2011. Public Health 2014; 128:777-83.
Schneeweiss S, Patrick AR, Stürmer T et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45:S131-S142.
Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015; 11:437-41.
Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63:8-18.
Holterhues C, Hollestein L, Nijsten T et al. Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991. Br J Dermatol 2013; 169:389-97.
Linos E, Swetter SM, Cockburn MG et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666-74.
Pottegård A, Friis S, Stürmer T et al. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol 2018; 122:451-9.
Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59:1104-9.
World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2021. Oslo, Norway 2020. Available at: https://www.whocc.no/atc_ddd_index/ (last accessed 12 March 2021).
Gandini S, Palli D, Spadola G et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018; 122:1-9.
Moscarelli L, Zanazzi M, Mancini G et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol 2010; 73:439-45.
Christian JB, Lapane KL, Hume AL et al. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 2008; 100:1223-32.